{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:47:07Z","timestamp":1769107627816,"version":"3.49.0"},"reference-count":29,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100013793","name":"PKD Charity","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013793","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kidney Care UK (previously BKPA) and British Renal Society Joint Grant"},{"name":"Addenbrookes Charitable Trust"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,4,5]]},"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vasopressin stimulates cyst growth in autosomal dominant polycystic kidney disease (ADPKD) leading to enlarged kidneys, hypertension and renal failure. Vasopressin receptor blockade slows disease progression. Physiological suppression of vasopressin secretion through high water (HW) intake could achieve a similar effect, necessitating a definitive large-scale trial of HW intake in ADPKD. The objective of the DRINK trial is to answer the key design and feasibility questions required to deliver a successful definitive water intake trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      We describe the design of a single-centre, open-label, prospective, randomised controlled trial. The \"\n                      <jats:bold>D<\/jats:bold>\n                      etermining feasibility of\n                      <jats:bold>R<\/jats:bold>\n                      andomisation to high vs. ad libitum water\n                      <jats:bold>In<\/jats:bold>\n                      take in Polycystic\n                      <jats:bold>K<\/jats:bold>\n                      idney Disease\" (DRINK) trial aims to enrol 50 patients with ADPKD, over the age of 16\u2009years with an estimated glomerular filtration rate (eGFR) \u226520\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . Participants will be randomised 1:1 to HW intake based on an individualised water intake prescription, or to ad libitum (AW) water intake. The HW group will aim for a dilute urine (urine osmolality \u2264270\u2009mOsm\/kg) as a surrogate marker of vasopressin suppression, and those in the AW group will target more concentrated urine. Participants will have an 8-week treatment period, and will be seen at weeks 0, 2, 4 and 8, undergoing assessments of fluid status, renal function and serum and urine osmolalities. They will receive dietary advice, and self-monitor urine specific gravity and fluid intake. The trial employs smartphone technology to permit home monitoring and remote direct data capture. The primary feasibility end points are recruitment rate and separation between arms in measured urinary osmolality. Key secondary assessments include acceptability, adherence, health-related quality of life, acute effects of HW intake on measured (\n                      <jats:sup>51<\/jats:sup>\n                      Cr-EDTA) and eGFR and ADPKD-related pain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was awarded by the East of England Essex Research Ethics Committee (16\/EE\/0026). The results of DRINK will be submitted to peer-reviewed journals, and presented to patients via the PKD Charity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT02933268\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial \">NCT02933268<\/jats:ext-link>\n                      and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT16794957\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial\">NCT16794957<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-022859","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:09:05Z","timestamp":1761581345000},"page":"e022859","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02933268","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct16794957","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ragada","family":"El-Damanawi","sequence":"first","affiliation":[{"name":"Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK"},{"name":"Cambridge Clinical Trials Unit, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tess","family":"Harris","sequence":"additional","affiliation":[{"name":"PKD Charity, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura B","family":"Mader","sequence":"additional","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge, UK"},{"name":"Patient Led Research Hub, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Bond","sequence":"additional","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Pavey","sequence":"additional","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard N","family":"Sandford","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian B","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK"},{"name":"Cambridge Clinical Trials Unit, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Burrows","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemyslaw","family":"Woznowski","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona E","family":"Karet Frankl","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F","family":"Hiemstra","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK"},{"name":"Cambridge Clinical Trials Unit, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"2025102708383857000_8.5.e022859.1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.59"},{"key":"2025102708383857000_8.5.e022859.2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv456"},{"key":"2025102708383857000_8.5.e022859.3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu087"},{"key":"2025102708383857000_8.5.e022859.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.05.004"},{"key":"2025102708383857000_8.5.e022859.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.39"},{"key":"2025102708383857000_8.5.e022859.6","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3283621510"},{"key":"2025102708383857000_8.5.e022859.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205511"},{"key":"2025102708383857000_8.5.e022859.8","doi-asserted-by":"crossref","unstructured":"Torres VE , Chapman AB , Devuyst O , et al . Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017;377.doi:10.1056\/NEJMoa1710030","DOI":"10.1056\/NEJMoa1710030"},{"issue":"Suppl 1","key":"2025102708383857000_8.5.e022859.9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"2025102708383857000_8.5.e022859.10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006030251"},{"key":"2025102708383857000_8.5.e022859.11","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00345.2014"},{"key":"2025102708383857000_8.5.e022859.12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","article-title":"Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a\u00a0pilot randomized controlled trial","volume":"68","author":"Amro","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025102708383857000_8.5.e022859.13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04180609"},{"key":"2025102708383857000_8.5.e022859.14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu093"},{"key":"2025102708383857000_8.5.e022859.15","doi-asserted-by":"crossref","unstructured":"Wong ATY , Mannix C , Grantham JJ , et al . Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 2018;8.","DOI":"10.1136\/bmjopen-2017-018794"},{"key":"2025102708383857000_8.5.e022859.16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"key":"2025102708383857000_8.5.e022859.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030"},{"key":"2025102708383857000_8.5.e022859.18","doi-asserted-by":"crossref","unstructured":"Luo X , Woznowski P , Burrows A , et al . SPLASH. New York, USA: ACM Press, 2016:1526\u201332.","DOI":"10.1145\/2851581.2892513"},{"key":"2025102708383857000_8.5.e022859.19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/ckj\/sfw153","article-title":"Patient survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey","volume":"10","author":"El-Damanawi","year":"2017","journal-title":"Clin Kidney J"},{"key":"2025102708383857000_8.5.e022859.20","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20424"},{"key":"2025102708383857000_8.5.e022859.21","doi-asserted-by":"crossref","first-page":"860-9","DOI":"10.1111\/nep.12675","article-title":"A systematic review to determine the most effective interventions to increase water intake","volume":"21","author":"Chua","year":"2016","journal-title":"Nephrology"},{"key":"2025102708383857000_8.5.e022859.22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1681\/ASN.V451159","article-title":"Glomerular filtration rate measurements in clinical trials","volume":"4","author":"Levey","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"2025102708383857000_8.5.e022859.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2025102708383857000_8.5.e022859.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/cclm-2014-0379","article-title":"Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology","volume":"52","author":"Bolignano","year":"2014","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"2025102708383857000_8.5.e022859.25","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.08.028"},{"key":"2025102708383857000_8.5.e022859.26","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328360a268"},{"key":"2025102708383857000_8.5.e022859.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2010.01.005"},{"key":"2025102708383857000_8.5.e022859.28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jpain.2015.01.012","article-title":"Validation of the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2) in acute low back pain","volume":"16","author":"Dworkin","year":"2015","journal-title":"J Pain"},{"key":"2025102708383857000_8.5.e022859.29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040448"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-022859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:09:09Z","timestamp":1761581349000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-022859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,9]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/bmjopen-2018-022859"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-022859","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}